drugset

drugset / Trial / NCT03897075

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

NCT03897075 ↗

Phase 3 Completed 99 enrolled Sun Pharmaceutical Industries, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

Timeline

Start: 2021-05-13
Primary completion: 2024-04-05
Completion: 2025-01-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tildrakizumab	Monoclonal antibody	—	—

Indications